Member Info for CB1984

In search of shares lol lol

Hi Sax pre the big fall they were talking £25 and that was before clev. Remember guys European pensions are invested here GLA

I got in the day after the mighty crash with Traumakine. CEO told everyone he had the answer .

Ask 380p

We want the interview with CEO.

360p BID 370p ASK

As previously communicated, four solid tumour cohorts in the first expansion stage (Part II) of the study (cutaneous melanoma, colorectal cancer (CRC), hepatocellular cancer and ovarian cancer) have demonstrated early signs of clinical efficacy from bexmarilimab therapy. This group is now joined by cholangiocarcinoma (also known as bile duct cancer) as a fifth responsive tumour cohort. The exact way how these cohorts will be taken forward into the protocol for Part III of the MATINS trial will be decided in Q3-2021 after further data on the effect of increased dosing frequency is available (recruitment currently ongoing). More frequent dosing either weekly or at two week intervals could increase bexmarilimab treatment efficacy further, compared to the original dosing interval of every three weeks, which has already led to some very promising results in several advanced cancer types.

Markku Jalkanen, Faron's CEO, said: "I am extremely happy about these results and wish to thank our team, our scientific network and the MATINS clinical group for the impressive work they have done, both progressing the trial and undertaking complex analyses of the data during challenging times in the face of the current pandemic. Never during my career have I seen that a high baseline count of regulatory T cells (Tregs) predicts a good response to a therapy. Until now, it has always been the opposite. This is remarkable. Such observations now provide us with a much better understanding of the next steps required for bexmarilimab's clinical development in pivotal studies and support its potential as a breakthrough therapy to deliver optimal clinical results in patients with hard to treat cancers.

Fantastic news , CEO was allways confident about clever gen

Many thanks zum zum. Looking forward to watching this. Refards. GLA

Very unusual that ceo has not done an interview on proactive investors. Any thoughts !!!!!

Would like an interview on proactive investor's.

33.9p Paid

Have emailed LSE asking where this morning's RNS is.

Its our secret, your chance to top up before everyone gets to know. GLA.

Opening price

Nice to see a positive forum this morning.

Can't believe the lack of enthusiasm on here. Disgraceful.

More games

I mean substantial amount lol